title: The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
abstract: OBJECTIVE
  To review phosphate-binder choice and mortality in hemodialysis patients.
  
  
  METHODS
  A literature search was performed using the PUBMED database to identify clinical trials published from January 1966 through January 2009. Search terms included: sevelamer and mortality, calcium acetate and mortality, and calcium carbonate and mortality.
  
  
  METHODS
  Clinical trials relating the effect of phosphate-binder choice on cardiovascular disease and mortality in hemodialysis patients, judged to be pertinent by the authors, were selected for discussion. DATA SYNTHESIS/CONCLUSIONS: The Renagel in New Dialysis (RIND) extension study and the Dialysis Clinical Outcomes Revisted (DCOR) study were the first clinical trials to compare the effects of calcium-based phosphate binders and sevelamer hydrochloride on mortality in hemodialysis patients. Based on the results of these and other studies evaluated, it is still unclear if sevelamer hydrochloride has a survival benefit in hemodialysis patients over calcium-based phosphate binders.
authors.affiliation: Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA.
authors.forename: Magdalene M
authors.initials: MM
authors.lastname: Assimon
authors.forename: Shaker
authors.initials: S
authors.lastname: Mousa
authors.forename: Olfat
authors.initials: O
authors.lastname: Shaker
authors.forename: Amy Barton
authors.initials: AB
authors.lastname: Pai
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D017610:Calcium Compounds / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology; D002614:Chelating Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy*; D011073:Polyamines / Q000627:therapeutic use; D006435:Renal Dialysis; D000069603:Sevelamer
chemical_list: D000085:Acetates; D017610:Calcium Compounds; D002614:Chelating Agents; D011073:Polyamines; D000069603:Sevelamer; D002119:Calcium Carbonate; C120662:calcium acetate